Please use a PC Browser to access Register-Tadawul
Get It
Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review
Arcutis Biotherapeutics -1.53%
Arcutis Biotherapeutics ARQT | 29.02 | -1.53% |
IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).
